Table 36.
Proportion of C. coli isolates from humans resistant to ciprofloxacin, erythromycin and tetracycline, 2016
| Country | Resistance to ciprofloxacin, erythromycin and tetracycline | |
|---|---|---|
| N | % Res | |
| Austria | 37 | 2.7 |
| Cyprus | 7 | NA |
| Estonia | 19 | 57.9 |
| Finlanda | 143 | 33.6 |
| Franceb | 850 | 5.1 |
| Italy | 11 | 27.3 |
| Lithuaniab | 40 | 12.5 |
| Luxembourg | 53 | 13.2 |
| Malta | 7 | NA |
| Netherlandsb | 99 | 6.1 |
| Portugal | 34 | 47.1 |
| Romania | 16 | 0.0 |
| Slovakiab | 41 | 0.0 |
| Slovenia | 130 | 1.5 |
| Spain | 38 | 21.1 |
| United Kingdom | 325 | 4.6 |
| Total (16 MSs) | 1,850 | 9.2 |
| Norway | 10 | 10.0 |
N: number of isolates tested; NA: not applicable; % Res: percentage of resistant isolates.
a
Travel‐associated cases, accounting for 65% of Campylobacter infections in Finland in 2016, could not be excluded from the Finnish AST data.
b
Data interpreted with clinical breakpoints.